Literature DB >> 9617981

Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments.

V Pérez1, N Bel, P Celada, J Ortiz, E Alvarez, F Artigas.   

Abstract

The relationship between peripheral serotonergic variables, melancholic traits, and clinical improvement after antidepressant treatment was examined in 83 drug-free major depressive patients. Plasma serotonin (5-HT) concentrations was lower in untreated melancholic patients (1.00 +/- 0.11 vs. 1.84 +/- 0.28 ng/mL, p < 0.008; N = 40 and 43, respectively). A tendency was observed for plasma 5-hydroxyindoleacetic acid (p < 0.06), whereas platelet 5-HT and plasma tryptophan did not differ between groups. After blood sampling and clinical ratings, treatment began with fixed doses of 5-HT uptake inhibitors (clomipramine or fluvoxamine), monoamine oxidase inhibitors, or tianeptine, a 5-HT uptake enhancer. There was no significant difference in response rates between patients with and without melancholic traits. The relationship between the clinical response at 6 weeks (>50% reduction of baseline Hamilton score) and the pretreatment values of biochemical variables was examined. Responders had a lower pretreatment platelet 5-HT (530 +/- 36 vs. 664 +/- 50 ng/10(9) platelets, p < 0.03; N = 44 and 39, respectively). Patients with a platelet 5-HT concentration above 800 ng/10(9) platelets had a lower response rate than those below this value (p < 0.003). This difference was maximal in the subgroup of patients treated with 5-HT uptake inhibitors (N = 49). In this subgroup, the response rates of patients with 5-HT concentrations below and above the cutoff point were, respectively, 70% and 17% (p < 0.001). A pretreatment platelet 5-HT value above 800 ng/10(9) platelets had a predictive value for a negative response of 92%. These results suggest the presence of biochemical differences in the peripheral serotonergic system between melancholic and nonmelancholic patients. The inverse relationship between the pretreatment platelet 5-HT content and clinical response may be useful in the investigation of the relationship between the 5-HT system and antidepressant response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9617981     DOI: 10.1097/00004714-199806000-00007

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

Review 1.  [Monoaminergic function in major depression. A possibly helpful tool for choosing treatment strategy].

Authors:  O Moeller; C Norra; G Gründer
Journal:  Nervenarzt       Date:  2006-07       Impact factor: 1.214

2.  Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.

Authors:  Craig H Mallinckrodt; John G Watkin; Chaofeng Liu; Madelaine M Wohlreich; Joel Raskin
Journal:  BMC Psychiatry       Date:  2005-01-04       Impact factor: 3.630

Review 3.  Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers.

Authors:  Bhautesh D Jani; Gary McLean; Barbara I Nicholl; Sarah J E Barry; Naveed Sattar; Frances S Mair; Jonathan Cavanagh
Journal:  Front Hum Neurosci       Date:  2015-02-02       Impact factor: 3.169

4.  Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders.

Authors:  Wonsuk Choi; Ju-Wan Kim; Hee-Ju Kang; Hee Kyung Kim; Ho-Cheol Kang; Ju-Yeon Lee; Sung-Wan Kim; Robert Stewart; Jae-Min Kim
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

5.  Platelet serotonin level and its correlation with finger length relation.

Authors:  Devasis Ghosh
Journal:  Indian J Psychiatry       Date:  2008-10       Impact factor: 1.759

6.  Effects of Ginseng Fruit Saponins on Serotonin System in Sprague-Dawley Rats with Myocardial Infarction, Depression, and Myocardial Infarction Complicated with Depression.

Authors:  Dong-Fang He; Yan-Ping Ren; Mei-Yan Liu
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.